Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Vitamin C  COVID-19 treatment studies for Vitamin C  C19 studies: Vitamin C  Vitamin C   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 44% Improvement Relative Risk Hospitalization time 38% Hamidi-Alamdari et al. NCT04370288 Vitamin C RCT LATE Is late treatment with vitamin C+combined treatments beneficial for COVID-19? RCT 80 patients in Iran Shorter hospitalization with vitamin C+combined treatments (p=0.004) Hamidi-Alamdari et al., Clinical and Translation.., doi:10.24875/RIC.21000028 Favors vitamin C Favors control
Methylene blue for treatment of hospitalized COVID-19 patients: a randomized, controlled, open-label clinical trial, phase 2
Hamidi-Alamdari et al., Clinical and Translational Investigation, doi:10.24875/RIC.21000028, NCT04370288 (history)
Hamidi-Alamdari et al., Methylene blue for treatment of hospitalized COVID-19 patients: a randomized, controlled, open-label clinical.., Clinical and Translational Investigation, doi:10.24875/RIC.21000028, NCT04370288
Mar 2021   Source   PDF  
  All Studies   Meta
RCT 80 hospitalized patients with severe COVID-19, 40 treated with methylene blue + vitamin C + N-acetylcysteine, showing lower mortality, shorter hospitalization, and significantly improved SpO2 and respiratory distress with treatment. NCT04370288 (history).
risk of death, 44.4% lower, RR 0.56, p = 0.38, treatment 5 of 40 (12.5%), control 9 of 40 (22.5%), NNT 10.0.
hospitalization time, 37.6% lower, relative time 0.62, p = 0.004, treatment 40, control 40.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Hamidi-Alamdari et al., 8 Mar 2021, Randomized Controlled Trial, Iran, peer-reviewed, 23 authors, this trial uses multiple treatments in the treatment arm (combined with methylene blue and N-acetyl cysteine) - results of individual treatments may vary, trial NCT04370288 (history).
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperVitamin CAll
Abstract: REVISTA DE INVESTIGACIÓN CLÍNICA Contents available at PubMed Rev Invest Clin. 2021;73(3):190-8 ORIGINAL ARTICLE Methylene Blue for Treatment of Hospitalized COVID-19 Patients: A Randomized, Controlled, Open-Label Clinical Trial, Phase 2 Daryoush Hamidi-Alamdari1*, Saied Hafizi-Lotfabadi2, Ahmad Bagheri-Moghaddam3, Hossin Safari4, Mahnaz Mozdourian5, Zahra Javidarabshahi5, Arash Peivandi-Yazdi5, Abass Ali-Zeraati6, Alireza Sedaghat5, Farid Poursadegh5, Fatemeh Barazandeh-Ahmadabadi2, Marzieh Agheli-Rad2, Seyed M. Tavousi6, Shohreh Vojouhi7, Shahram Amini8, Mahnaz Amini5, Seyed Majid-Hosseini9, Ashraf Tavanaee-Sani10, Amin Ghiabi11, Shima Nabavi-Mahalli9, Negar Morovatdar12, Omid Rajabi13, and George Koliakos14 1Surgical Oncology Research Center; 2Department of Internal Medicine, Shariati Hospital; 3Department of Anesthesiology, Faculty of Medicine; 4Infectious Diseases Ward, Hasheminejad Hospital; 5Lung Diseases Research Center; 6Kidney Transplantation Complications Research Center, Faculty of Medicine; 7Metabolic Syndrome Research Center, School of Medicine; 8Anaesthesiology and Critical Care Lung Research Center, Faculty of Medicine; 9Department of Internal Medicine, Emamreza Hospital; 10Department of Infectious diseases, Emamreza Hospital; 11Department of Internal Medicine, Ghaem Hospital; 12Clinical Research Development Unit, Imam Reza Hospital, Faculty of Medicine, and 13Department of Pharmaceutical Control, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran; 14Department of Biochemistry, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece ABSTRACT Background: There is no pharmacological intervention on the treatment of hypoxemia and respiratory distress in COVID-19 patients. Objective: The objective of the study was to study the effect of the reduced form of methylene blue (MB) on the improvement of oxygen saturation (SpO2) and respiratory rate (RR). Methods: In an academic medical center, 80 hospitalized patients with severe COVID-19 were randomly assigned to receive either oral MB along with standard of care (SOC) (MB group, n = 40) or SOC only (SOC group, n=40). The primary outcomes were SpO2 and RR on the 3rd and 5th days. The secondary outcomes were hospital stay and mortality within 28 days. Results: In the MB group, a significant improvement in SpO2 and RR was observed on the 3rd day (for both, p < 0.0001) and also the 5th day (for both, p < 0.0001). In the SOC group, there was no significant improvement in SpO2 (p = 0.24) and RR (p = 0.20) on the 3rd day, although there was a significant improvement of SpO2 (p = 0.002) and RR (p = 0.01) on the 5th day. In the MB group in comparison to the SOC group, the rate ratio of increased SpO2 was 13.5 and 2.1 times on the 3rd and 5th days, respectively. In the MB group compared with the SOC group, the rate ratio of RR improvement was 10.1 and 3.7 times on the 3rd and 5th days, respectively. The hospital stay was significantly shortened in the MB group (p = 0.004), and the mortality was 12.5% and 22.5% in the MB and SOC groups, respectively. Conclusions: The addition of MB to the treatment protocols significantly improved SpO2 and respiratory distress in COVID-19 patients, which resulted in decreased hospital stay and mortality. NCT04370288 (REV INVEST CLIN. 2021;73(3):XX-XX) Key words: COVID-19. Treatment. Methylene Blue. Hypoxemia. Mortality. *Corresponding..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop